相关实验视频

Updated: Jul 8, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

免疫检查点抑制剂诱导的胆管炎:对药监数据的分析

Lucy Meunier¹, Lina Hountondji², Hélène Jantzem³

¹Department of Hepatogastroenterology and Liver Transplantation, Universitary Hospital Centre Montpellier, University of Montpellier, Montpellier, France; Institute for Regenerative Medicine and Biotherapy, University of Montpellier, Montpellier, France.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

|December 18, 2023

概括

免疫检查点抑制剂 (ICI) 可以导致肝损伤,包括ICI诱导的胆管炎. 这项研究分析了法国药监数据,以描述ICI诱导的胆管炎,有助于更好地管理患者.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
肝病学肝病学是一种肝病学.

背景情况:

免疫检查点抑制剂 (ICI) 提供显著的抗癌益处,但可能导致与免疫相关的不良反应 (irAEs).
检查点抑制剂诱导的肝损伤 (CHILI) 影响高达25%的患者,胆管炎是新兴的irAE.
目前对ICI诱导胆管炎的管理指南是有限的,需要进一步的文件.

研究的目的:

为了分析在法国药监系统中报告的ICI诱导胆管炎病例.
描述ICI诱导的胆管炎的临床特征,演变和结果.
为改善临床管理策略提供数据.

主要方法:

对向法国药监系统报告的ICI诱导胆管炎病例的回顾性分析.
收集关于临床表现,诊断结果,治疗和患者结果的数据.
基于报告的数据,基于ICI诱导的胆管炎的特征.

主要成果:

详细分析ICI诱导胆炎病例的临床特征和演变.
评估治疗反应和患者的治疗结果.
识别ICI诱导的结肠炎的模式和趋势.

结论:

由ICI诱导的胆脉炎是一种具有显著意义的irAE,具有特定的临床特征和结果.
需要进一步的研究来完善ICI引起的胆道炎的管理策略.
药监数据对于理解和管理新疗法的罕见不良事件至关重要.

更多相关视频

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...